Table 1.

Description of the 295 cases treated with LNZ and comparison with controls in the GAMES IE cohort.

Variables (%)	LNZ 295	Controls 3172	P	95% CI Lower-Upper
Age, median (IQR)	69 (58 – 76)	69 (57 – 77)	.98	–
Sex (males)	187 (63.4)	1921 (60.5)	.37	–
Comorbidities
Ischemic heart disease	79 (26.7)	815 (25.6)	.74	–
Heart failure	131 (44.4)	1020 (32.1)	<.01	1.68 (1.32–2.14)
Diabetes mellitus	94 (31.9)	870 (27.5)	.25	–
Renal failure	62 (21.0)	473 (15.0)	.02	1.57 (1.22–2.03)
Previous IE	23 (7.8)	230 (7.3)	.78	–
Charlson index (median, IQR)	5 (3 – 7)	5 (3 – 7)	.51	–
Type of IE
Aortic	116 (39.3)	1580 (49.8)	<.01	0.65 (0.51–0.83)
Mitral	104 (35.3)	1390 (43.8)	< .01	0.69 (0.54–0.89)
Tricuspid	21 (7.1)	163 (5.1)	.15	–
Native	145 (49.2)	1965 (61.9)	<.01	0.59 (0.47–0.75)
Prosthetic	4 (31.9)	46 (29.8)	.45	–
Non-valvular	69 (23.4)	358 (11.3)	<.01	2.39 (1.78–3.20)
Acquisition
Community	136 (47.6)	1873 (61.5)	<.01	0.56 (0.44–.072)
Nosocomial	126 (44.1)	900 (29.6)	<.01	1.87 (1.46–2.39)
Healthcare-related	24 (8.4)	271 (8.9)	.77	–
Etiology
S. aureus	84 (28.5)	692 (21.8)	.01	1.42 (1.09–1.86)
Coagulase negative staphylococci	88 (29.8)	522 (16.5)	<.01	2.15 (1.65–2.81)
Enterococcus spp.	36 (12.2)	436 (13.7)	.46	–
Streptococcus spp.	34 (11.5)	847 (26.7)	<.01	0.35 (0.24–0.56)
Complications
Persistent bacteremia	47 (15.9)	349 (11.0)	.01	1.56 (1.12–2.18)
Central nervous system involvement	49 (16.6)	624 (19.6)	.23	–
Renal failure	139 (47.1)	1108 (35.2)	<.01	1.63 (1.28–2.08)
Septic shock	56 (18.9)	364 (11.4)	<.01	1.79 (1.31–2.45)
Cardiac surgery	146 (49.5)	1414 (44.6)	.11	–
Clinical course
Median in-hospital stay (days, IQR)	39 (27 – 61)	36 (21 – 52)	<.01	1.01 (1.00–1.02)
Median duration of treatment for IE (days, IQR)	42 (26 – 50)	36 (25 – 44)	<.01	1.05 (1.02–1.08)
In-hospital mortality	91 (30.8)	856 (27.0)	.16	–
One-year follow-up mortality	12 (4.0)	186 (5.8)	.25	–
Recurrences	6 (3.1)	52 (2.4)	.73	–

Bold indicates not significant (NS).